Overview
Background
Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School.
Having trained in Brisbane and Toronto, Dr Mollee has developed an international reputation studying amyloidosis and the plasma cell dyscrasias. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia, Australian Amyloidosis Network, National Blood Cancer Taskforce and is a member of the AACB Monoclonal Gammopathy Working Group and the International Kidney & Monoclonal Gammopathy Research Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) and current Chair of the Australian Amyloidosis Network. He heads the Myeloma Service as well as the Queensland Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Qualifications
- Masters (Coursework) of Medical Science, University of Newcastle
- Royal Australasian College of Physicians, Royal Australasian College of Physicians
- Royal College of Pathologists of Australasia, Royal College of Pathologists of Australasia
Research impacts
The research of the Queensland Amyloidosis Centre aims to improved the diagnosis, monitoring and therapy of all types of amyloidosis. The Centre, in collaboration with Pathology Queensland and the Translational Research Institute, developed laser capture macrodisscution and tandem mass spectrometry analysis to accurately diagnosis the type of amyloidosis that patients have and have introuduced this assay into the clinical laboratory. Research to improve the diagnosis and monitoring of this rare disease has also assessed immunoglobulin free light chain assays, bone scintigraphy and novel radionuclide PET tracers. The Queensland Amyloidosis Centre maintains an active clinical trial program in amyloidosis therapies including both investigator-initiated and commercial studies.
Works
Search Professor Peter Mollee’s works on UQ eSpace
2023
Conference Publication
Outcomes of Second Line Therapy for Light Chain Amyloidosis after Initial Therapy with a Bortezomib Based Regimen
Chakravorty, Lipi, Gibbons, Anthea, Anderson, Nirija, Kwok, Fiona, Korczyk, Dariusz, Abro, Emad Uddin, Lam, Stephanie, Gibbs, Simon, Mollee, Peter and Sidiqi, M. Hasib (2023). Outcomes of Second Line Therapy for Light Chain Amyloidosis after Initial Therapy with a Bortezomib Based Regimen. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-186335
2023
Conference Publication
A Prospective, Multinational Study of Clinical and Biological Factors Associated with Short Overall Survival in Multiple Myeloma
Tang, Andy, Kim, Kihyun, Chen, Fiona, McQuilten, Zoe K., Mollee, Peter, Rajagopal, Rajeev, Quach, Hang, Ho, Phoebe Joy, Harrison, Simon J., Spencer, Andrew and Chng, Wee-Joo (2023). A Prospective, Multinational Study of Clinical and Biological Factors Associated with Short Overall Survival in Multiple Myeloma. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-178192
2023
Conference Publication
High Frequency of HLA-Class II B Cell Receptor Neoantigens in IGHV Mutated-CLL
Sabdia, Muhammed B., Burgess, Melinda, Law, Soi Cheng, Thurgood, Lauren A., Kazakoff, Stephen, Swain, Fiona, Tobin, Joshua W.D., Mollee, Peter, Patch, Ann-Marie and Gandhi, Maher K (2023). High Frequency of HLA-Class II B Cell Receptor Neoantigens in IGHV Mutated-CLL. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-174149
2023
Conference Publication
Identifying Early Suboptimal Hematological Response in Patients with AL Amyloidosis Treated with Bortezomib-Based Chemotherapy
Gibbons, Anthea, Ranjit Anderson, Nirija, Chakravorty, Lipi, Kwok, Fiona, Sidiqi, Hasib, Gibbs, Simon, Korczyk, Dariusz, Abro, Emad Uddin and Mollee, Peter (2023). Identifying Early Suboptimal Hematological Response in Patients with AL Amyloidosis Treated with Bortezomib-Based Chemotherapy. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-179219
2023
Conference Publication
Serial 18F-Florbetaben Positron Emission Tomography and Cardiac Magnetic Resonance Imaging in the Evaluation of Systemic Light Chain Cardiac Amyloidosis Enhances Diagnostic and Response Assessment Accuracy
Ranjit Anderson, Nirija, Law, W. Phillip, Dong, Xin, Ng, Arnold C.T and Mollee, Peter (2023). Serial 18F-Florbetaben Positron Emission Tomography and Cardiac Magnetic Resonance Imaging in the Evaluation of Systemic Light Chain Cardiac Amyloidosis Enhances Diagnostic and Response Assessment Accuracy. 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-186377
2023
Conference Publication
Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand)
Quach, Hang, Lasica, Masa, Low, Michael, Mollee, Peter, Lai, Hock Choong, Wong Doo, Nicole, Hocking, Jay, Campbell, Philip, Murphy, Nicholas E., Sidiqi, M. Hasib, Routledge, David, Heenan, Jessica, Horvath, Noemi, Eek, Richard, Renwick, William E. P., Lenton, Douglas Stuart, Child, Lauren J, McCaughan, Georgia, Butcher, Belinda E, Mazumdar, Deepmala and Kalff, Anna (2023). Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand). 65th ASH Annual Meeting, San Diego, CA United States, 9-12 December 2023. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2023-185169
2023
Journal Article
Screening for and diagnosis of monoclonal gammopathy
Chong, Yuh Ping, Lim, Say Min, Loh, Tze Ping, Mollee, Peter, Wijeratne, Nilika and Choy, Kay Weng (2023). Screening for and diagnosis of monoclonal gammopathy. Journal of Clinical Pathology, 76 (11), 727-733. doi: 10.1136/jcp-2023-208774
2023
Conference Publication
Imaging cardiac amyloidosis using 18F-florbetaben positron electron topography (PET) in systemic light chain (AL) amyloidosis
Anderson, Nirija Ranjit, Tobin, Joshua, Law, Phillip and Mollee, Peter (2023). Imaging cardiac amyloidosis using 18F-florbetaben positron electron topography (PET) in systemic light chain (AL) amyloidosis. International Myeloma Society 20th Annual Meeting and Exposition, Athens, Greece, 27-30 September 2023. New York, NY United States: Elsevier. doi: 10.1016/s2152-2650(23)02059-1
2023
Journal Article
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia
Cass, S. H., Tobin, J. W. D., Seo, Y. D., Gener-Ricos, G., Keung, E. Z., Burton, E. M., Davies, M. A., McQuade, J. L., Lazar, A. J., Mason, R., Millward, M., Sandhu, S., Khoo, C., Warburton, L., Guerra, V., Haydon, A., Dearden, H., Menzies, A. M., Carlino, M., Smith, J. L., Mollee, P., Burgess, M., Mapp, S., Keane, C., Atkinson, V., Parikh, S. A., Markovic, S. N., Ding, W., Call, T. G. ... Ferrajoli, A. (2023). Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Annals of Oncology, 34 (9), 796-805. doi: 10.1016/j.annonc.2023.06.007
2023
Conference Publication
Identifying early suboptimal haematological response in patients with AL amyloidosis treated with bortezomib-based chemotherapy
Mollee, Peter, Gibbons, Anthea, Anderson, Niri Ranjit, Korczyk, Dariusz, Gibbs, Simon and Sidiqi, Hasib (2023). Identifying early suboptimal haematological response in patients with AL amyloidosis treated with bortezomib-based chemotherapy. International Myeloma Society 20th Annual Meeting and Exposition, Athens, Greece, 27-30 September 2023. New York, NY United States: Elsevier. doi: 10.1016/s2152-2650(23)02056-6
2023
Conference Publication
Localised light chain (AL) amyloidosis: presentation, treatment and outcomes; an observational study
Anderson, Nirija Ranjit, Abro, Emad, Korczyk, Dariusz and Mollee, Peter (2023). Localised light chain (AL) amyloidosis: presentation, treatment and outcomes; an observational study. International Myeloma Society 20th Annual Meeting and Exposition, Athens, Greece, 27-30 September 2023. New York, NY United States: Elsevier. doi: 10.1016/s2152-2650(23)02060-8
2023
Journal Article
Safety, feasibility, and acceptability of a multi-site individualized exercise intervention for people with multiple myeloma
Nicol, Jennifer L., Cunningham, Brent, Woodrow, Carmel, Adlard, Kirsten, Papinczak, Zoe, Spence, Rosalind R., Boytar, Alex N., Mollee, Peter, Weber, Nicholas, Nicol, Andrew J., Hill, Michelle M. and Skinner, Tina L. (2023). Safety, feasibility, and acceptability of a multi-site individualized exercise intervention for people with multiple myeloma. Medicine and Science in Sports and Exercise, 55 (12), 2214-2227. doi: 10.1249/mss.0000000000003267
2023
Journal Article
Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myeloma
Teh, Benjamin W., Reynolds, Gemma, Slavin, Monica A., Cooley, Louise, Roberts, Matthew, Liu, Eunice, Thursky, Karin, Talaulikar, Dipti, Mollee, Peter, Szabo, Ferenc, Ward, Chris, Chan, Henry, Prince, H. Miles, Harrison, Simon J. and the Medical and Scientific Advisory Group, Myeloma Australia and National Centrefor Infections in Cancer (2023). Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myeloma. Internal Medicine Journal, 53 (8), 1469-1477. doi: 10.1111/imj.16100
2023
Conference Publication
More Efficient Delivery Of High-cost Standard-of-care Therapies In Relapsed Multiple Myeloma Using Real-time Feedback Of Patient-reported Outcome Measures: The My-prompt-2 Trial
Moore, Elizabeth, Harrison, Simon, Ho, P. Joy, Irving, Adam, King, Tracy, Mccaughan, Georgia, Mcquilten, Zoe, Mollee, Peter, Park, Susanna, Petrie, Dennis, Reynolds, John, Rutherford, Claudia, van Tonder, Tina, Wellard, Cameron, Wood, Erica and Spencer, Andrew (2023). More Efficient Delivery Of High-cost Standard-of-care Therapies In Relapsed Multiple Myeloma Using Real-time Feedback Of Patient-reported Outcome Measures: The My-prompt-2 Trial. EHA2023, Online, 8 - 15 June 2023. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1097/01.hs9.0000977464.68933.f0
2023
Journal Article
Cardiac “hypertrophy” phenotyping: differentiating aetiologies with increased left ventricular wall thickness on echocardiography
Ferkh, Aaisha, Tjahjadi, Catherina, Stefani, Luke, Geenty, Paul, Byth, Karen, De Silva, Kasun, Boyd, Anita C., Richards, David, Mollee, Peter, Korczyk, Dariusz, Taylor, Mark S., Kwok, Fiona, Kizana, Eddy, Ng, Arnold C. T. and Thomas, Liza (2023). Cardiac “hypertrophy” phenotyping: differentiating aetiologies with increased left ventricular wall thickness on echocardiography. Frontiers in Cardiovascular Medicine, 10 1183485. doi: 10.3389/fcvm.2023.1183485
2023
Journal Article
The importance of frailty assessment in multiple myeloma: A position statement from The Myeloma Scientific Advisory Group (MSAG) to myeloma Australia
Sim, Shirlene, Kalff, Anna, Tuch, Gina, Mollee, Peter, Ho, Joy, Harrison, Simon, Gibbs, Simon, Prince, H. Miles, Spencer, Andrew, Joshua, Douglas, Lee, Cindy, Ling, Silvia, Murphy, Nick, Szabo, Ferenc, Szer, Jeff, Weber, Nicholas, Ward, Christopher, Talaulikar, Dipti, Zannettino, Andrew and Quach, Hang (2023). The importance of frailty assessment in multiple myeloma: A position statement from The Myeloma Scientific Advisory Group (MSAG) to myeloma Australia. Internal Medicine Journal, 53 (5), 819-824. doi: 10.1111/imj.16049
2023
Journal Article
Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia
Burgess, Melinda, Keane, Colm, Tobin, Joshua W. D., Law, Soi Cheng, Griffin, Alison, Gill, Devinder, Ewing, Adam D., Atkinson, Victoria, Mollee, Peter, Sabdia, Muhammed B., Saunders, Nicholas and Gandhi, Maher K. (2023). Resolution of melanoma to PD-1 blockade but simultaneous rapid progression of concomitant chronic lymphocytic leukemia. Acta Haematologica, 146 (2), 166-171. doi: 10.1159/000527631
2023
Journal Article
Safety, feasibility, and efficacy of exercise interventions for people with multiple myeloma: a systematic review
Nicol, Jennifer L., Chong, Jamie E., McQuilten, Zoe K., Mollee, Peter, Hill, Michelle M. and Skinner, Tina L. (2023). Safety, feasibility, and efficacy of exercise interventions for people with multiple myeloma: a systematic review. Clinical Lymphoma, Myeloma and Leukemia, 23 (2), 86-96. doi: 10.1016/j.clml.2022.10.003
2023
Journal Article
Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphoma
Mistry, Vijay, Scott, Justin R., Wang, Tzu-Yang, Mollee, Peter, Miles, Kenneth A., Law, W. Phillip and Hapgood, Greg (2023). Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphoma. Cancer Imaging, 23 (1) 11, 1-11. doi: 10.1186/s40644-023-00520-7
2023
Journal Article
The second revision of the International Staging System (R2‐ISS) stratifies progression‐free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population
Tan, Joanne L. C., Wellard, Cameron, Moore, Elizabeth M., Mollee, Peter, Rajagopal, Rajeev, Quach, Hang, Harrison, Simon James, McDonald, Emma‐Jane, Ho, P. Joy, Prince, H. Miles, Augustson, Bradley M., Campbell, Philip, McQuilten, Zoe K., Wood, Erica M., Spencer, Andrew and Myeloma and Related Diseases Registry Investigators (2023). The second revision of the International Staging System (R2‐ISS) stratifies progression‐free and overall survival in multiple myeloma: Real world data results in an Australian and New Zealand Population. British Journal of Haematology, 200 (2), e17-e21. doi: 10.1111/bjh.18536
Supervision
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Master Philosophy
Novel Radionuclide Tracers for Imaging in Amyloidosis
Principal Advisor
Other advisors: Associate Professor Colm Keane
-
Doctor Philosophy
Addressing frailty in older people with haematological malignancies
Associate Advisor
Other advisors: Associate Professor Emily Gordon, Dr Natasha Reid, Professor Ruth Hubbard
Media
Enquiries
For media enquiries about Associate Professor Peter Mollee's areas of expertise, story ideas and help finding experts, contact our Media team: